Specifically, this observation suggests that IL‐6 elevation in the medium may also serve a diagnostic role in addition to its well‐established role as a prognostic indicator of myocardial infarction and heart failure.[65, 66] Moreover, the absence of elevated IL‐6 medium concentrations at days 5 and 7 in the LPS/IFN‐γ‐treated systems support a role for this cytokine in targeted, tissue‐specific compound damage. The gene discussed is IFNG; the disease is heart failure.